FGFR2 and cancer: Kim Kim S-B S-B First-in-human phase I study of aprutumab ixadoti, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer First-in-human phase I study of aprutumab ixadoti, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer Target Oncol Target Oncol 2019 2019 14 14 591 591 601 601 supplied-pmid 31502117?